China's Rare Mutation Collaboration Group on Lung Cancer officially established to focus on "rare patients" in large cancer strains

On May 13, 2020, the China Lung Cancer Rare Mutation Collaboration Group was launched online, marking the official establishment of China's first collaboration group for rare mutations in lung cancerUnder the guidance of the Chinese Society for Cancer Cancer, the China Clinical Oncology Association (CSCO), the Chinese Rare Mutation Collaboration Group (Rare Mutation Soma) of China, together with clinicians, pathologists, joint diagnostic and testing companies and pharmaceutical companies, focuses on the current situation of treatment of rare mutations in lung cancer, aims to create a complete ecological closed loop through innovative cooperation models, provide smiclit target academic exchange platform, promote testing norms, strengthen scientific cooperation, andco-founder of the China Lung Cancer Rare Mutation Collaboration Group, Professor Zhang Zhang, Director of The Oncology Prevention center of Zhongshan University, said that lung cancer treatment is changing rapidly, precision medicine has developed rapidly in recent years, second-generation sequencing technology has been widely used in clinical practice, more and more patients have been detected rare genetic mutations, but there are not enough treatment methods and treatment informationIt is also based on this situation, China's lung cancer rare mutation collaboration group was establishedThe team hopes to work with the wider community to share up-to-date treatment progress and case information on rare mutations and how to bring better treatment to patients with rare mutations"Rare patients"in thelarge cancer population
According to the National Cancer Center released in January 2019, the number of lung cancer cases in China is 784,000, the largest cancer in ChinaNon-small cell lung cancer is also the most common lung cancer, accounting for about 85% of the total number of lung cancer patientsWith the rapid development of precision treatment of lung cancer, more and more lung cancer targets have been approved for market, bringing more and better choices for patients' treatmentHowever, compared with EGFR, ALK, ROS1, which have the corresponding target drug targets, rare targets c-Met, Her-2, RET treatment status is not satisfactory, in the clinical guidelines, has not yet recommended the corresponding first-line targeted therapeutic drugsPatients with rare mutations at the corresponding targets have also become "rare patients" under the large cancer population, in urgent need of new treatment drugs and social attentionclinical studies have welcomed new hope in patients with rare mutations
met a mutation is one of the typical rare mutations in lung cancer patients In non-small cell lung cancer, met mutation patients have poor prognosis, are insensitive to existing standard treatments, and the total lifetime (OS) of traditional chemotherapy treatment is only six months in recent years, there has been a lot of research on rare target c-Met, but not many bright-eyed breakthroughs, and with the recent development of basic and clinical research, as well as new and exciting research results, c-Met target drug research and development has once again gained industry attention several clinical trials of MET mutations are currently under way Among them, "Wallitinib's study of MET exosphory 14 jumping lung sarcoma (PSC) and other types of non-small cell lung cancer (NSCLC)" is an open label, one-arm, multi-center Phase II clinical trial conducted in China The results of phase II studies have now been published with an initial effective rate of more than 50%, which offers survival hope in patients with lung cancer caused by MET mutations the field of rare mutations requires more attention and more integration and input of resources The establishment of the China Lung Cancer Rare Mutation Collaboration Group is conducive to the integration of the industry's rare mutation diagnosis and treatment resources, mobilize the detection companies, pharmaceutical companies, social groups and doctors and experts and other aspects of enthusiasm, focus on the advantages of production and research, improve the level of rare mutation treatment, and promote the development of more new drugs At the same time, it will help to attract the attention of the community to the group of patients with rare mutations, optimize the complete ecological chain of diagnosis and treatment, attract more research and development investment, establish and improve the network of collaborative diagnosis and treatment of rare mutations, promote standardized detection and scientific treatment of patients with rare mutations, effectively safeguard the health rights and interests of patients with rare mutations, and contribute to the construction of healthy China 2030 Source: